Erythromelalgia is rare, often underrecognized, and frequently mismanaged—yet much of the morbidity is preventable with a simple, structured algorithm. Up to 15% of primary cases involve SCN9A sodium-channel variants, and a meaningful subset are secondary to myeloproliferative neoplasms (MPNs). This post distills what busy clinicians need now: crisp diagnostic criteria, high-yield differentials, targeted testing, and a practical treatment pathway you can apply in the next clinic.
Defining erythromelalgia and why an evidence-based management algorithm matters
Erythromelalgia presents with paroxysmal burning pain, erythema, and warmth—typically in the feet or hands—triggered by heat or exertion and relieved by cooling. The pattern is distinctive yet overlaps with infection, neuropathy, and ischemia, which drives misdiagnosis and overtreatment. A standardized, evidence-based workflow reduces unnecessary antibiotics, imaging, and ER returns.
An algorithmic approach anchors rapid triage, focused labs, and targeted therapy. It ensures you don’t miss MPN-associated disease that responds dramatically to antiplatelet therapy, or inherited sodium-channel variants where sodium-channel blockers can help. This article provides that pathway for 2026 practice.
Erythromelalgia diagnostic criteria: clinical features, triggers, and documentation standards
Diagnosis is clinical: recurrent distal burning pain with erythema and warmth, precipitated by heat/exercise and relieved by cooling/elevation. Document symmetry, distribution (toes/soles > fingers), skin temperature, and flare duration. Photograph flares when possible; between attacks, the exam may be normal.
Capture triggers and modifiers in a flare diary. Note heat exposure, exertion, alcohol/spicy foods, and seasonal patterns. Record response to rest, elevation, or cooling; persistent immersion suggests severe pain and raises injury risk.
Red flags and initial triage: unilateral vs bilateral, infectious mimics, acute vascular compromise
Screen first for red flags—acute limb ischemia, rapidly progressive infection, or compartment syndrome. Unilateral, cold, pulseless, pale/cyanotic limbs, neurologic deficit, or sudden escalation of pain warrants urgent vascular evaluation.
Distinguish bilateral heat-triggered pain from infectious cellulitis. Fever, lymphangitis, leukocytosis, expanding erythema with tenderness favor infection; EM flares improve with cooling/elevation and lack systemic toxicity. When in doubt, mark borders, reassess at 24–48 hours, and avoid premature antibiotics.
Differential diagnosis: erythromelalgia vs small fiber neuropathy (SFN)—key historical, exam, and testing distinctions
SFN causes length-dependent burning pain with sensory loss to pin/thermal and normal nerve conduction studies; EM adds visible erythema/warmth during flares. Confirm SFN with quantitative sensory testing and reduced intraepidermal nerve fiber density (IENFD) on skin biopsy.
In EM, triggers are thermal/exertional and cooling brings relief; in SFN, symptoms are steadier and not heat-limited. Between flares, EM exam may normalize; SFN often shows persistent small-fiber sensory changes. Document both patterns to guide therapy and patient expectations.
Distinguishing erythromelalgia from cellulitis and CRPS: pattern recognition, course, and response to cooling/elevation
Cellulitis usually progresses over days with tenderness, warmth, and systemic signs; EM flares are episodic, heat-induced, and rapidly improve with cooling. If borders expand despite rest/cooling, treat as infection and follow antimicrobial guidance.
CRPS localizes to an inciting injury, features sensory, vasomotor, sudomotor/edema, and motor/trophic changes across categories. EM lacks mechanical allodynia-driven spread and typically has predictable heat triggers and cooling relief. Re-examine at different temperatures to unmask diagnostic clues.
Rule out peripheral vascular disease and neuropathic/autoimmune mimics: ABI, Doppler, vasculitis labs, and skin changes
Measure ABI and, when indicated, perform segmental Dopplers in atypical, unilateral, or exertional-predominant cases. Abnormal ABI or exam asymmetry should pivot your workflow to vascular imaging and risk reduction.
If rash features suggest vasculitis (palpable purpura, livedo with ischemic changes), add ANCA, CBC, CMP, urinalysis, and consider biopsy. Use targeted serologies per ACR/Vasculitis Foundation guidance and escalate promptly for organ-threatening disease.
Screening for myeloproliferative neoplasms (essential thrombocythemia and others): CBC, JAK2/CALR/MPL testing, and referral thresholds
Any EM patient with thrombocytosis deserves an MPN screen—CBC trend plus JAK2 V617F, CALR, and MPL. Bone marrow evaluation and risk stratification follow if positive.
Refer to hematology for platelet count ≥450 × 10^9/L with a driver mutation, unexplained progressive thrombocytosis, erythrocytosis, leukocytosis, splenomegaly, or microvascular events. 2022 ICC/WHO updates emphasize integrated molecular and marrow criteria, not platelets alone.
Pathophysiology overview to guide therapy: microvascular dysregulation, sodium channel variants, platelet-mediated mechanisms
Two dominant mechanisms inform treatment: microvascular dysregulation and neuronal hyperexcitability. In primary EM, gain-of-function variants in NaV1.7 (SCN9A) lower firing thresholds of nociceptors; in secondary EM (especially MPNs), platelet-mediated microthrombosis drives acral ischemia.
Physiologic studies show arteriovenous shunting with reduced nutritive capillary perfusion during flares, explaining heat sensitivity and cooling relief. Platelet activation markers fall with aspirin when MPN-associated EM improves, supporting an antiplatelet-first strategy in that subgroup.
Evidence-based erythromelalgia treatment algorithm: stepwise approach from trigger control to targeted pharmacotherapy
Start simple, escalate deliberately, and tailor to mechanism. Our 5-step algorithm synthesizes high-quality reviews, with emphasis on safety and rapid wins.
1) Noninjurious cooling + trigger control; 2) Identify/tx secondary causes (MPN, autoimmune, drug-related); 3) Topicals (lidocaine, compounded agents) and oral neuropathic analgesics; 4) Mechanism-targeted therapy (aspirin for MPN-EM; sodium-channel blockers for inherited/neuronal hyperexcitability); 5) Interventional pain options for refractory disease.
First-line measures: behavioral modifications, cooling protocols without injury risk, footwear, moisturization, and flare diaries
Cooling helps—cold injury hurts. Use fans, cool rooms, brief cool-water rinses, and breathable footwear; avoid prolonged ice-water immersion and direct ice.
Moisturize, protect skin, and record triggers in a flare diary. Persistent soaking leads to maceration, ulcers, and infection; counsel early about safer cooling and skin care routines.
Aspirin response in erythromelalgia associated with myeloproliferative neoplasms: dosing, onset, predictors, and monitoring
MPN-associated EM often shows rapid, marked relief with low-dose aspirin. Classic physiologic studies demonstrate reversal of platelet consumption and symptom resolution after aspirin therapy
Expect improvement within hours to days; lack of response suggests non-platelet mechanisms. Confirm MPN status, review bleeding risk (especially with extreme thrombocytosis/acquired vWF defects), and coordinate with hematology for cytoreduction when indicated.
Neuromodulatory options: sodium channel blockers (mexiletine, lidocaine infusions), gabapentinoids, SNRIs, TCAs—selection and titration
Sodium-channel blockers can help inherited/neuronal EM. Case and translational data support mexiletine or IV lidocaine trials in selected patients.
For broad neuropathic control, consider gabapentinoids, SNRIs, or TCAs with slow titration and side-effect monitoring. Use neuropathic pain guidance to select classes and set expectations; brief inpatient IV lidocaine trials may identify oral responders.
Adjuncts and interventional strategies: topical agents, botulinum toxin, sympathetic blocks, spinal cord stimulation—when to consider
Topical lidocaine and compounded agents may give focal relief; refractory focal areas sometimes respond to botulinum toxin. Small case literature supports trialing onabotulinumtoxinA when standard therapy fails.
Sympathetic blocks, dorsal root ganglion or spinal cord stimulation are last-line options for severe, disabling disease. Offer in experienced centers after mechanism-based pharmacotherapy and behavioral interventions plateau.
Monitoring, safety, and outcomes: assessing treatment response, avoiding cooling injury, managing polypharmacy, and quality-of-life metrics
Track both pain and function using validated tools. The Brief Pain Inventory (BPI) is quick to administer and pairs well with visit-to-visit decisions.
When to refer: hematology for MPN-positive disease, neurology/dermatology for diagnostic uncertainty, pain specialists for refractory cases
Refer early when the mechanism is unclear or response is incomplete. Hematology manages MPN-positive disease and cytoreduction; neurology/dermatology adjudicate SFN vs EM or atypical rashes; pain specialists guide lidocaine/mexiletine trials and neuromodulation.
Use explicit triggers for referral. These include positive driver mutations, unexplained thrombocytosis, limb-threatening ischemia, progressive ulceration, or repeated ED visits for uncontrolled flares despite first- and second-line therapy.
Special populations and considerations: pediatric presentations, pregnancy, and comorbid dysautonomia or SFN
Pediatric EM often presents early, with strong heat triggers and SCN9A variants; sodium-channel strategies may be more fruitful. Families benefit from education on safe cooling and school accommodations.
In pregnancy, emphasize nonpharmacologic strategies and specialist input for medication safety. For coexisting SFN/dysautonomia, tailor neuropathic regimens and hydration/temperature control, and avoid polypharmacy.
Practical takeaways and the algorithm for streamlined, evidence-based erythromelalgia management
A clear, mechanism-informed algorithm prevents delays, reduces harm, and improves quality of life. Anchor the diagnosis in classic flares, rule out emergencies, screen for MPNs, and pick treatments that match the driver—antiplatelet therapy for platelet-mediated disease, and sodium-channel strategies for neuronal hyperexcitability.
Use noninjurious cooling, track outcomes, and escalate thoughtfully with subspecialty support.
